Title : Efinaconazole
Text : {{Infobox drug
| drug_name = 
| IUPAC_name =  (2''R'',3''R'')-2-(2,4-Difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1''H''-1,2,4-triazol-1-yl)-2-butanol
| image = Efinaconazole.svg
| alt = 
| caption =

<!-- Clinical data -->
| tradename = Jublia, Clenafin
| Drugs.com = 
| MedlinePlus = 
| licence_US = Efinaconazole
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = Rx-only
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = Rx-only
| legal_status = 
| routes_of_administration = Topical ([[solution]])

<!-- Pharmacokinetic data -->
| bioavailability = Unknown (oral)
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number = 164650-44-6
| ATCvet = 
| ATC_prefix = D01
| ATC_suffix = AC19
| PubChem = 489181
| ChemSpiderID = 428538
| DrugBank =
| ChEBI_Ref = {{ebicite|correct|EBI}} 
| ChEBI = 82718
| KEGG = D10021

<!-- Chemical data -->
| C=18 | H=22 | F=2 | N=4 | O=1
| molecular_weight  = 348.39 g/mol
| smiles = C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3
| StdInChI = 1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1
| StdInChIKey = NFEZZTICAUWDHU-RDTXWAMCSA-N
}}

'''Efinaconazole''' (trade names '''Jublia''' and '''Clenafin''') is a [[triazole antifungal]]. It is approved for use in Canada, Japan and the United States as a 10% topical solution for the treatment of [[onychomycosis]] (fungal infection of the [[Nail (anatomy)|nail]]).<ref>{{cite journal | journal = Drugs | date = Nov 2013 | volume = 73 | issue = 17 | pages = 1977–1983 | doi = 10.1007/s40265-013-0152-x | title = Efinaconazole: first global approval |vauthors=Patel T, Dhillon S | pmid= 24249649}}</ref><ref>{{cite journal | pmid= 23377392 | journal = J Drugs Dermatol | date=Feb 2013 | volume = 12 | issue = 2 | pages = 186–192 | title = Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study |vauthors=Tschen EH, Bucko AD, Oizumi N, Kawabata H, Olin JT, Pillai R }}</ref>  Efinaconazole acts as a [[Lanosterol 14 alpha-demethylase|14α-demethylase]] [[enzyme inhibitor|inhibitor]].<ref>{{cite journal |vauthors=Tatsumi Y, Nagashima M, Shibanushi T | title = Mechanism of action of efinaconazole, a novel triazole antifungal agent | journal = Antimicrob Agents Chemother | date = May 2013 | volume = 57 | issue = 5 | pages =2405–2509 | doi=10.1128/aac.02063-12|display-authors=etal| pmc=3632939 }}</ref><ref name="drugsatfda">{{cite web |title = Drugs at FDA: JUBLIA |url = http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203567s000lbl.pdf |accessdate = 26 June 2014}}</ref>

==Medical uses==
In two clinical trials 17.8% and 15.2% of patients using efinaconazole were cured, compared to 3.3% and 5.5% of patients using a placebo.<ref name="drugsatfda" />

Efinaconazole is not especially effective, but it is currently the best topical treatment available, with cure rates two or three times better than the next best topical treatment, [[ciclopirox]]. It is considered a reasonable option for patients with mild cases, or patients who can not take oral treatment.<ref name="podiatrytoday">{{cite web |title = A Closer Look At A New Topical Option For Onychomycosis |url = http://www.podiatrytoday.com/blogged/closer-look-new-topical-option-onychomycosis |accessdate = 21 May 2015}}</ref>

==History==
In 2014, the U.S. [[Food and Drug Administration]] (FDA) approved the [[New Drug Application]] (NDA).<ref name="valeant">{{cite web | url=http://ir.valeant.com/investor-relations/news-releases/news-release-details/2014/Valeant-Pharmaceuticals-Announces-FDA-Approval-Of-Jublia-for-the-Treatment-of-Onychomycosis/default.aspx | title=Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosis | work=Valeant Pharmaceuticals | date=9 June 2014 | accessdate=1 November 2015 | location=Laval, Quebec}}</ref> According to [[Valeant Pharmaceuticals|Valeant Pharmaceuticals International Inc]] CEO [[J. Michael Pearson]] they acquired Jublia through their purchase of Dow Pharmaceutical Sciences in 2008.<ref name="valeant" />

==Cost==
In 2015 the cost of treatment with efinaconazole in the United States was said to be $2317 ''per nail''.<ref name=Mikailov>{{cite journal |vauthors=Mikailov A, Cohen J, Joyce C, Mostaghimi A | title = Cost-effectiveness of Confirmatory Testing Before Treatment of Onychomycosis | journal = JAMA Dermatology |year = 2015| url= http://archderm.jamanetwork.com/article.aspx?articleid=2475012 | pmid = 26716567 | doi = 10.1001/jamadermatol.2015.4190 | pages=1–6}}</ref>

==References==
{{reflist}}

{{Antifungals}}

[[Category:Lanosterol 14α-demethylase inhibitors]]
[[Category:Fluoroarenes]]
[[Category:Tertiary alcohols]]
[[Category:Triazole antifungals]]
